PRPF40A: A Potential Drug Target and Biomarker (G55660)

Target Name: PRPF40A

NCBI ID: G55660

PRPF40A

PRPF40A: A Potential Drug Target and Biomarker

PRPF40A, also known as formin binding protein 3 (FBP-3), is a protein that plays a critical role in the regulation of cell growth and differentiation. It is a member of the FBP family, which includes several similar proteins that are involved in the regulation of cell mechanics, including FBP1, FBP2, and FBP3. PRPF40A is unique in that it is expressed in the brain and is involved in the regulation of neuronal excitability, synaptic plasticity, and neurotransmitter release.

The discovery of PRPF40A as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of neurological and psychiatric disorders. PRPF40A has been shown to play a role in the regulation of neurotransmitter release and has been implicated in the development of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

In addition to its potential therapeutic applications, PRPF40A also has significant potential as a biomarker for certain neurological disorders. The regulation of neurotransmitter release is a critical aspect of brain function, and changes in neurotransmitter release levels can be an indication of underlying neurological disorders. PRPF40A has been shown to be involved in the regulation of neurotransmitter release and has been used as a biomarker for the diagnosis and treatment of certain neurological disorders.

One of the key challenges in the development of new treatments for neurological disorders is the difficulty of targeting specific proteins involved in the regulation of neurotransmitter release. PRPF40A is a protein that is expressed in the brain and has been shown to play a critical role in the regulation of neurotransmitter release. By targeting PRPF40A, researchers may be able to develop new treatments that specifically target this protein and improve the effectiveness of these treatments.

In addition to its potential therapeutic and biomarker applications, PRPF40A is also of interest to researchers as a potential drug target. The regulation of neurotransmitter release is a critical aspect of brain function, and changes in neurotransmitter release levels can be an indication of underlying neurological disorders. By targeting PRPF40A, researchers may be able to develop new treatments that specifically target this protein and improve the effectiveness of these treatments.

In conclusion, PRPF40A is a protein that has significant potential as a drug target and biomarker for the treatment of neurological disorders. Its role in the regulation of neurotransmitter release and its expression in the brain make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of PRPF40A in the regulation of neurotransmitter release and its potential as a drug target and biomarker.

Protein Name: Pre-mRNA Processing Factor 40 Homolog A

Functions: Binds to WASL/N-WASP and suppresses its translocation from the nucleus to the cytoplasm, thereby inhibiting its cytoplasmic function (By similarity). Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape and migration. May play a role in cytokinesis. May be involved in pre-mRNA splicing

The "PRPF40A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRPF40A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets